Baxter may stay out of Heparin business

Apr 25, 2008

The head of Baxter International Inc. said the company has not decided whether it will resume selling the blood thinner heparin in the United States.

Baxter recalled vials of the drug two months ago after reports of allergic reactions. The U.S. Food and Drug Administration said the drug may have been intentionally contaminated with an animal-like substance to increase supplier profits.

The drug generates $30 million of Baxter's more than $11 billion in annual sales, the Chicago Tribune said Thursday. The newspaper said Wall Street analysts asked Chairman and Chief Executive Robert Parkinson last week if was worth the legal risks to remain in the heparin business.

"We haven't made a decision whether or not we are going to re-enter (the market) with heparin," Parkinson said.

Copyright 2008 by United Press International

Explore further: Study examines FDA influence on design of pivotal drug studies

add to favorites email to friend print save as pdf

Related Stories

FDA tells doctors new heparin formula less potent

Oct 01, 2009

(AP) -- The Food and Drug Administration is alerting doctors that a widely used blood thinner has been reformulated to improve its safety, though the change could open the door to dosing errors.

Researchers unravel heparin death mystery

Apr 23, 2008

An international team of researchers led by MIT has explained how contaminated batches of the blood-thinner heparin were able to slip past traditional safety screens and kill dozens of patients recently in ...

FDA to test all heparin at U.S. border

Mar 16, 2008

The U.S. Food and Drug Administration has issued an import alert and plans to test all shipments of the drug heparin before they enter the country.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

18 minutes ago

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

23 hours ago

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

Health care M&A leads global deal surge

Nov 23, 2014

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.